Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b lorpucitinib study in familial adenomatous polyposis
NL-OMON52152Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of lorpucitinib in Colonic Adenomatous Polyposis, sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage Change from Baseline in Colorectal Polyp Burden for all Polyps at Week 24 and Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24. Started Nov 2021; status: active, not recruiting.
02
Drugs
lorpucitinib
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON52152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52152.